Company Overview and News

19
Deals of the day-Mergers and acquisitions

6h reuters
Oct 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday:
FOX FBU STAN FCREY FRCEF FBU 580001 STAB STAN EPW STAC 2888 SCBFF AAPL GNC HRS IOF FOXA DIS

19
Deals of the day-Mergers and acquisitions

10h reuters
Oct 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 10.00 GMT on Monday:
FOX FBU STAN FCREY FRCEF FBU 580001 STAB STAN EPW STAC 2888 SCBFF AAPL GNC HRS IOF FOXA DIS

 
Centrica subsidiary to buy U.S.-based retail electricity business

12h reuters
* Centrica subsidiary Direct Energy Business has agreed to buy the retail electricity business of Source Power and Gas LLC, a wholly owned indirect U.S. subsidiary of Australian power company ERM Power Limited, Centrica said on Monday
EPW

 
Drought may increase push for electricity royal commission

2018-09-05 theage.com.au
Analysts say a worsening drought may drive up wholesale power prices, acting as a potential launching pad for a royal commission by a government focused on cutting electricity costs.
EPW

 
Drought may increase push for electricity royal commission

2018-09-05 smh.com.au
Analysts say a worsening drought may drive up wholesale power prices, acting as a potential launching pad for a royal commission by a government focused on cutting electricity costs.
EPW

 
Power couple make $750,000 investment to fight homelessness

2018-06-10 smh.com.au
Brisbane power couple Trevor and Judith St Baker have put their money where their mouth is to make the largest single private donation to the help the homeless in Queensland.
EPW

 
Bright Brisbane sparks charge electric cars all around the world

2018-03-22 smh.com.au
Three Brisbane blokes are charging ahead in the lucrative electric car market despite Queenslanders being slow to adopt the global trend.
EPW

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:EPW / ERM POWER LIMITED on message board site Silicon Investor.

epwn epwn epwn